These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Modern approach to the treatment of decompensated heart failure. Vilas-Boas F Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):159-67. PubMed ID: 19210212 [TBL] [Abstract][Full Text] [Related]
24. The role of venodilators in the perioperative management of heart failure. Valchanov KP; Arrowsmith JE Eur J Anaesthesiol; 2012 Mar; 29(3):121-8. PubMed ID: 22273830 [TBL] [Abstract][Full Text] [Related]
26. Nesiritide: the latest drug for treating heart failure. Fontana D Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809 [No Abstract] [Full Text] [Related]
27. [What is new in the medical management of acute heart failure?]. Meyer P; White M; Keller RF; Lerch R; Hullin R Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757 [TBL] [Abstract][Full Text] [Related]
29. [The treatment of cardiac insufficiency with vasodilators]. Biollaz J; Munafo A Schweiz Med Wochenschr; 1988 Apr; 118(17):616-20. PubMed ID: 3381076 [TBL] [Abstract][Full Text] [Related]
30. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM; J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433 [TBL] [Abstract][Full Text] [Related]
32. The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations. Heywood JT; Khan TA Rev Cardiovasc Med; 2007; 8 Suppl 5():S22-9. PubMed ID: 18192950 [TBL] [Abstract][Full Text] [Related]
33. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Jain P; Massie BM; Gattis WA; Klein L; Gheorghiade M Am Heart J; 2003 Feb; 145(2 Suppl):S3-17. PubMed ID: 12594447 [No Abstract] [Full Text] [Related]
34. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Damman K; Voors AA; Hillege HL; Navis G; Lechat P; van Veldhuisen DJ; Dargie HJ; Eur J Heart Fail; 2010 Sep; 12(9):974-82. PubMed ID: 20685688 [TBL] [Abstract][Full Text] [Related]
35. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931 [TBL] [Abstract][Full Text] [Related]
37. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
38. Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Rapp JA; Gheorghiade M Heart Fail Clin; 2005 Apr; 1(1):77-93. PubMed ID: 17386836 [No Abstract] [Full Text] [Related]
39. The benefits of early vasoactive therapy in the treatment of acute decompensated heart failure. Albert NM J Am Acad Nurse Pract; 2005 Oct; 17(10):403-10. PubMed ID: 16181262 [TBL] [Abstract][Full Text] [Related]
40. [Recent advances and limitations of medical treatment on heart failure]. Momomura S Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]